Curevo Vaccines is focused on strategic partnerships combining excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development



As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high quality science of a research organization with the product development capabilities of a biotech company to create new vaccines, diagnostics and drugs. IDRI’s role in Curevo is to provide scientific expertise in vaccine, adjuvant and formulation development, as well as contribute its experience in successfully navigating the regulatory approval process through U.S. and international agencies. IDRI will also oversee the conduct of cGMP manufacturing of adjuvants and formulations, as well as clinical studies to advance vaccine through the clinical pipeline.


Mogam Institute for Biomedical Research

As a nonprofit global research organization, MIBR (Mogam Institute for Biomedical Research) is engaged in basic discovery research to combat infectious diseases, cancer, and rare diseases. Founded in 1983, MIBR is headquartered in southern Seoul with a number of research collaborations ongoing with GC Pharma. MOGAM Institute’s role in Curevo will provide expertise in the design and preclinical optimization of protein subunit vaccines.

GC Pharma

GC Pharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for more than half a century. GC Pharma brings knowledge in manufacturing and process development of vaccine material for clinical studies and product development.